Navigation Links
New Report Analyzes Key Controversies in Multiple Sclerosis Treatment
Date:11/14/2007

SCOTTSDALE, Ariz., Nov. 14 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for MS therapies.

In this report, entitled "MedPredict Thought Leader Insight & Analysis: Multiple Sclerosis," physician experts discuss the key controversies emerging from ECTRIMS (European Committee for Treatment and Research in MS) 2007, including:

-- Early aggressive therapy vs. more conservative approaches.

-- The negative results from REGARD, and implications for the powering of

MS trials. The report offers predictions on results expected in the

BEYOND, PreCISe and OLYMPUS.

-- The potential for pulmonary delivery of interferon and Copaxone.

-- The numerous orally available drugs in development for MS. The report

reviews the benefits and drawbacks of fingolimod, other S1Ps,

short-acting VLA4, teriflunomide, laquinimod, fampridine, fumarates and

other oral options, and predicts where they will fall on the

safety/efficacy spectrum.

-- The status and potential of a number of vaccine approaches.

-- Intriguing neuroprotection / neuroregeneration strategies, including

LINGO, anti-myelin-associated-glycoprotein MAb and remyelination MAb.

Drugs/Mechanisms mentioned in this report include: S1P agonists (fingolimod; Novartis, S1P1; Roche/Actelion, Sphingomab; Lpath, S1P1 modulators; Epix / Amgen), inhibitors of DNA synthesis/repair (teriflunomide; Sanofi-Aventis, cladribine; Ivax/Serono), potassium channel blockers (fampridine; Acorda, BNC-245; Bionomics), interferons (Avonex; Biogen, Rebif; Ares-Serono, Betaseron; Bayer-Schering and Biferonex; Biopartners Holdings), VLA4 inhibitors (Tysabri; Biogen/Elan, firategrast; GlaxoSmithKline, CDP-323; UCB/Biogen; ATL1102 (Antisense Therapeutics), B-cell inhibitors (rituximab; Biogen/Genentech/Roche, ocrelizumab; Genentech/Roche, CamPath/alemtuzumab; Genzyme / Bayer-Schering, ofatumumab; Genmab/GSK, GA-101; Glycart / Roche), Anti-CD-25 (daclizumab; PDL/Biogen/Roche), other autoimmune suppressants (laquinimod; Teva), myelin basic proteins (Copaxone; Teva, PI-2301 (Peptimmune), MBP8298; BioMS, BHT-3009; Bayhill, Tovaxin; Opexa, NeuroVax; Orchestra, VG-1000/RTL-1000; Artielle), fumartes (BG-12; Biogen), hormonal therapy (estriol; Pipex, testosterone; UCLA), anti-myelin-associated-glycoprotein MAb (GSK), Neurodex (dextromethorphan + quinidine; Avanir), Remyelination MAb (Acorda / Mayo).

About MedPredict

MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.


'/>"/>
SOURCE MedPredict Market Research
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. QMed, Inc. Reports July Medicare SNP Enrollments
3. Phlo Affiliate Reports Expanded Coverage to Oregon Border
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Avitar Reports Third Quarter Financial Results for Fiscal 2007
8. Response Genetics Reports Second Quarter 2007 Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Transgenomic, Inc. Reports Second Quarter 2007 Results
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , Jan. 18, 2017   Parent Project ... fight to end Duchenne muscular dystrophy (Duchenne) , ... the New Jersey Institute of Technology (NJIT) and Talem ... exploration of robotic technology to assist people living ... incorporate NJIT,s technology – an embedded computer, software, a ...
(Date:1/18/2017)... , ... January 18, 2017 , ... ... Dr. Dante Leven successfully implanted SpineFrontier’s A-CIFT™ Solofuse-P™. The operation took place on ... Valley Stream, NY. The procedure was an anterior cervical discectomy and fusion on ...
(Date:1/18/2017)... ... January 18, 2017 , ... Announced in December ... Institutes (MII). U.S. Secretary of Commerce Penny Pritzker has announced the award of ... of Defense has announced the award of a new Advanced Regenerative Manufacturing Institute ...
(Date:1/18/2017)... ... 2017 , ... Researchers from a new study are stating that if levels of ... cancer treatment, this indicates there is still remaining prostate cancer cells that are more likely ... test has always been an indicator of whether a man’s prostate cancer is growing ...
Breaking Biology Technology:
(Date:1/18/2017)... Minn. , Jan. 18, 2017 ... technology company that supports the entire spectrum of ... has been another record-breaking year for the organization ... market interest in MedNet,s eClinical products and services. ... the tremendous marketplace success of iMedNet ...
(Date:1/12/2017)... , Jan. 12, 2017  New research undertaken by ... office of the future.  1,000 participants were simply asked which ... months which we may consider standard issue.  Insights on what ... 2017 were also gathered from futurists and industry leaders including ... James Canton .  Some of ...
(Date:1/11/2017)... NEW BRUNSWICK, N.J. , Jan. 11, 2017  Michael Johnson, ... from Foundation Venture Capital Group, Inc., has been named to the ... Johnson, 27,  was one of 600 people in 20 fields ... only four percent of the 15,000 applicants were selected. ... He is currently a PhD ...
Breaking Biology News(10 mins):